Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
A Hauschild, U Trefzer, C Garbe, KC Kaehler… - Melanoma …, 2008 - journals.lww.com
Systemic treatment of metastatic melanoma is of low efficacy, and new therapeutic strategies
are needed. Histone deacetylase inhibitors are supposed to restore the expression of tumor
suppressor genes and induce tumor cell differentiation, growth arrest, and apoptosis. This
study was aimed to evaluate the efficacy, safety, and pharmacokinetics of the histone
deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate
(MS-275) in patients with pretreated metastatic melanoma. Patients with unresectable AJCC …
are needed. Histone deacetylase inhibitors are supposed to restore the expression of tumor
suppressor genes and induce tumor cell differentiation, growth arrest, and apoptosis. This
study was aimed to evaluate the efficacy, safety, and pharmacokinetics of the histone
deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate
(MS-275) in patients with pretreated metastatic melanoma. Patients with unresectable AJCC …